1. Consolidated Financial Results for the Six Months Ended September 30, 2017
(April 1, 2017 to September 30, 2017)





3. Forecast of Consolidated Earnings for the Year Ending March 31, 2018 (April 1, 2017 to March 31, 2018)



* Notes to consolidated financial statements
(1) Significant changes in subsidiaries during the period (Scope of consolidation): None
(2) Adoption of accounting method specific to the preparation of consolidated quarterly financial statements:
Adopted
(Note) For further details, refer to “(4) Notes to Consolidated Financial Statements” (Adoption of
Accounting Method Specific to the Preparation of Quarterly Consolidated Financial Statements) in
“2.Consolidated Financial Statements for the Six Months” on page 9 of Attached Documents.
(3) Changes in accounting principles and accounting estimates and retrospective restatement
1) Changes in accounting principles due to amendment to accounting standards: None
2) Changes other than above: None
3) Changes in accounting estimates: None
4) Retrospective restatement: None
(4) Number of shares issued and outstanding (Common stock)
1) Number of shares issued and outstanding at end of the period (treasury stock included):
Six months ended September 30, 2017: 532,463,527 shares
Year ended March 31, 2017: 532,463,527 shares
2) Number of treasury stock at end of the period:
Six months ended September 30, 2017: 1,404,659 shares
Year ended March 31, 2017: 1,388,394 shares
3) Average number of shares outstanding during the quarter:
Six months ended September 30, 2017: 531,067,502 shares
Six months ended September 30, 2016: 531,664,892 shares
* This financial results report for the first half quarter is exempt from quarterly review.
* Notes
All descriptions about the future of the Company contained herein including earnings forecasts are
prepared on the basis of data and information currently in our possession as well as certain assumptions that
are deemed reasonable, and therefore are not meant to have us committed to their achievement. Various
factors may cause actual results to substantially differ from those described herein.